In Silico Identification of Novel Drug Targets for Campylobacter Jejuni and Potential Drug Molecules

Abstract

Campylobacter jejuni is the main responsible organism of Campylobacteriosis, a diarrhoea-like condition involving symptoms like nausea, vomiting, enteralgia and, in critical cases, reactive arthritis and Guillain-Barré syndrome. Usually, this disease is treated without antibiotics, but antibiotic therapy is important for patients with severe sickness as well as post-infection problems. Campylobacter is a gram-negative bacterium that has acquired antibiotic resistance due to drug overuse and misuse, which has led to a search for new antibiotics against C. jejuni, as it continues to remain untreated with the already available drugs on the market, like, Azithromycin, Erythromycin, Ciprofloxacin, Tetracycline, etc.